Flamel Technologies, Inc

Latest News

April 25, 2008
Flamel Technologies Presents Results of Two Week Study of Interferon Alpha XL at the European Association for the Study of the Liver

March 4, 2008
Flamel Technologies Fourth Quarter and Year End 2007 Earnings Results Conference Call,
8:30 EST

March 3, 2008
Flamel Technologies Announces Fourth Quarter and Year-End Results; Fourth quarter includes strong clinical results; new agreements; and cash maintained at $41 million

March 3, 2008
Flamel Technologies Announces Nomination of Dr. Frank Fildes to Board of Directors; Flamel Technologies also announces departure of Michel Finance and appointment of Sian Crouzet

Medusa®

A Versatile Nano Carrier for the Delivery of Native Proteins

Medusa®, a self-assembled poly-aminoacid nanoparticles system, is a versatile protein carrier for the development of novel and second-generation long-acting native protein drugs. more info

Also available:
"Novel sustained release formulation of IFN-alfa-2b-XL, improves tolerability and demonstrates potent viral load reduction in a phase I/II HCV clinical trial" click here

"Novel Sustained Release Formulation of IL-2 Improves Pharmacokinetics Performance
and Demonstrates Potent Activation of Immunological Cell Line" click here

Micropump® Technologies

From Pediatric to Geriatric Uses

Controlled-release systems permitting either extended (Micropump® I) or both delayed and extended (Micropump® II) delivery of small molecule drugs.

more info

November 14, 2001 Flamel Technologies announces funded feasibilty study with a major bio-pharmaceutical company using its Medusa® technology.

October 30, 2001 Flamel Technologies announces third quarter results, loss per share of $(0.04).

October 23, 2001 Flamel Technologies S.A. announces completion of human proof of concept study for controlled-release antibiotic.

October 10, 2001 Flamel Technologies announces licensing agreement with Merck & Co., Inc..

September 27, 2001 Flamel Technologies announces negative response of French authorities on filing of Genvir® for registration.

August 24, 2001 Flamel Technologies announces the resignation of Jean Deleage as a board member.

July 30, 2001 Flamel Technologies announces second quarter and first half of 2001.

July 12, 2001 Flamel Technologies announces a feasibility study employing Medusa®; positive phase I results with Micropump ® and departure of Michael Myers.

April 30, 2001 Flamel Technologies announces first quarter results, reducing loss per share to $(0.05) on higher revenues.

March 15, 2001 Flamel Technologies announces 2000 results

January 10, 2001 Flamel Technologies announces two new Micropump® feasability studies with major pharmaceutical companies, change to NASDAQ trading symbol

January 4, 2001 Flamel Technologies to work with Connetics Corporation on new feasability study utilizing Medusa®, Flamel's patented protein delivery technology